Aptevo Therapeutics Inc (APVO) Stock Price

APVOStock

$2.46−93.24%52W

Market Cap$4.43M

P/E—

PEG Ratio—

Div yield—

Beta1.73

APVO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-75.17%

Price vs S&P 500 (4W)-45.81%

VGM Score6.85

Book Value / Share (Quarterly)$9.65

P/TBV (Annual)3.99x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-22.41

Price vs S&P 500 (YTD)-86.40%

Gross Margin (TTM)51.39%

Net Profit Margin (TTM)-222.55%

EPS (TTM)$-197.29

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-197.29

EPS (Annual)$-62.63

ROI (Annual)-504.73%

Gross Margin (Annual)51.39%

Net Profit Margin (5Y Avg)-114.17%

Cash / Share (Quarterly)$12.07

ROA (Last FY)-153.93%

EBITD / Share (TTM)$-46.56

ROE (5Y Avg)-609.94%

Operating Margin (TTM)-154.97%

Cash Flow / Share (Annual)$-25.65

P/B Ratio0.44x

P/B Ratio (Quarterly)0.43x

Net Income / Employee (Annual)$-727,300

EV / Revenue (TTM)-0.72x

ROA (TTM)-117.06%

EV / EBITDA (TTM)-1.29x

EPS Incl Extra (Annual)$-62.63

Current Ratio (Annual)3.81x

Quick Ratio (Quarterly)3.23x

3-Month Avg Trading Volume0.05M

52-Week Price Return-93.24%

EV / Free Cash Flow (Annual)-2.00x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$100.30

P/S Ratio (Annual)1.66x

Asset Turnover (Annual)0.09x

52-Week High$48.78

Operating Margin (5Y Avg)-235.75%

EPS Excl Extra (Annual)$-62.63

Tangible BV CAGR (5Y)-25.04%

26-Week Price Return-63.92%

Quick Ratio (Annual)3.71x

13-Week Price Return-52.18%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.36x

Enterprise Value$-9.36M

Asset Turnover (TTM)0.22x

Book Value / Share Growth (5Y)-36.29%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)7.97x

Pretax Margin (Annual)225.24%

Cash / Share (Annual)$21.67

3-Month Return Std Dev75.54%

Gross Margin (5Y Avg)41.27%

Net Income / Employee (TTM)$-795,600

ROE (Last FY)-504.73%

EPS Basic Excl Extra (Annual)$-62.63

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-197.29

Receivables Turnover (Annual)0.00x

ROI (TTM)-198.50%

P/S Ratio (TTM)0.40x

Pretax Margin (5Y Avg)-269.14%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$100.30

Price vs S&P 500 (52W)-111.55%

Year-to-Date Return-74.44%

5-Day Price Return-16.90%

EPS Normalized (Annual)$-62.63

ROA (5Y Avg)-56.80%

Net Profit Margin (Annual)257.77%

Month-to-Date Return-41.36%

Cash Flow / Share (TTM)$-2.16

EBITD / Share (Annual)$-101.84

Operating Margin (Annual)274.28%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-164.78%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-197.29

P/TBV (Quarterly)3.99x

P/B Ratio (Annual)0.51x

Inventory Turnover (TTM)7.97x

Pretax Margin (TTM)-228.06%

Book Value / Share (Annual)$17.42

Price vs S&P 500 (13W)-54.98%

Beta1.73x

Revenue / Share (TTM)$0.00

ROE (TTM)-198.50%

52-Week Low$2.38

mGradeF

vgmGradeF

APVO Earnings Surprise History

Q2 25-151.20est. -1497.60

Q3 25-40.14est. -37.62

Q1 26-6.41est. -5.60

Q2 26-5.31est. -6.20

APVO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
APVOAptevo Therapeutics Inc	—	—	F	$2.46
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Aptevo Therapeutics Inc

Aptevo Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic cancer treatments using its proprietary ADAPTIR platform technology. The company's lead clinical programs include ALG.APV-527 targeting co-stimulatory receptors and CD3xCD123 for acute myelogenous leukemia, with additional preclinical candidates in development. ADAPTIR enables the generation of monospecific, bispecific, and multi-specific antibodies designed to enhance immune response against cancer cells.